2014 Angiotensin Gordon Research Conference and Gordon Research Seminar

2014年血管紧张素戈登研究会议暨戈登研究研讨会

基本信息

批准号：
8719379
负责人：
Lisa A Cassis
金额：
$ 1万
依托单位：
GORDON RESEARCH CONFERENCES
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8719379
关键词：
AGTR2 gene Academia Acute Adverse effects Aging Agonist Aldosterone Aldosterone Receptors Aldosterone Synthase Aminopeptidase Angiopoietin-2 Angiotensin II Angiotensin II Signaling Pathway Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Angiotensin-Converting Enzyme Inhibitors Angiotensinogen Angiotensins Ants Area Atherosclerosis Award Basic Science Biological Markers Boxing Cardiovascular Diseases Chymase Clinic Clinical Clinical Pathology Clinical Sciences Collaborations Critiques Data Development Diabetes Mellitus Discipline Drug resistance Electrolyte Balance Enzymes Epigenetic Process Event Fostering France Functional disorder Future G-Protein-Coupled Receptors Gender Generations Genomics Head Heart failure Hypertension Hypotension Industry Insulin Insulin Receptor Intervention Kentucky Kidney Leadership Metabolic Mineralocorticoid Receptor Modality Names Nerve Degeneration Netherlands Obesity Oral Oranges Paris, France Pathway interactions Patients Peptides Peptidyl-Dipeptidase A Pharmaceutical Preparations Pharmacologic Substance Play Postdoctoral Fellow Pre-Eclampsia Process Proteomics Published Comment Receptor Signaling Receptor, Angiotensin, Type 1 Renin Renin-Angiotensin System Renin-Angiotensin-Aldosterone System Research Research Personnel Resistant Hypertension Role Running Scientific Advances and Accomplishments Scientist Series Signal Pathway Signal Transduction Signs and Symptoms Speed Stress Students Syndrome System Techniques Testing Texas Time Tissues Travel Universities Voting aminopeptidase B analog angiotensin I (1-7)angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-bench to bedside blood pressure regulation career clinically relevant college extracellular glutamyl aminopeptidase graduate student hyperkalemia inhibitor/antagonist meetings member posters public health relevance receptor respiratory social symposium tool urinary

AGTR2 gene Academia Acute Adverse effects Aging Agonist Aldosterone Aldosterone Receptors Aldosterone Synthase Aminopeptidase Angiopoietin-2 Angiotensin II Angiotensin II Signaling Pathway Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Angiotensin-Converting Enzyme Inhibitors Angiotensinogen Angiotensins Ants Area Atherosclerosis Award Basic Science Biological Markers Boxing Cardiovascular Diseases Chymase Clinic Clinical Clinical Pathology Clinical Sciences Collaborations Critiques Data Development Diabetes Mellitus Discipline Drug resistance Electrolyte Balance Enzymes Epigenetic Process Event Fostering France Functional disorder Future G-Protein-Coupled Receptors Gender Generations Genomics Head Heart failure Hypertension Hypotension Industry Insulin Insulin Receptor Intervention Kentucky Kidney Leadership Metabolic Mineralocorticoid Receptor Modality Names Nerve Degeneration Netherlands Obesity Oral Oranges Paris, France Pathway interactions Patients Peptides Peptidyl-Dipeptidase A Pharmaceutical Preparations Pharmacologic Substance Play Postdoctoral Fellow Pre-Eclampsia Process Proteomics Published Comment Receptor Signaling Receptor, Angiotensin, Type 1 Renin Renin-Angiotensin System Renin-Angiotensin-Aldosterone System Research Research Personnel Resistant Hypertension Role Running Scientific Advances and Accomplishments Scientist Series Signal Pathway Signal Transduction Signs and Symptoms Speed Stress Students Syndrome System Techniques Testing Texas Time Tissues Travel Universities Voting aminopeptidase B analog angiotensin I (1-7)angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-bench to bedside blood pressure regulation career clinically relevant college extracellular glutamyl aminopeptidase graduate student hyperkalemia inhibitor/antagonist meetings member posters public health relevance receptor respiratory social symposium tool urinary

展开

项目摘要

DESCRIPTION (provided by applicant): The renin-angiotensin system (RAS) plays a vital role in virtually every cardiovascular disease, and drugs blocking this system are currently widely used. Three classes can be distinguished (renin inhibitors, ACE inhibitors and angiotensin II type 1 (AT1) receptor antagonists), which in essence all block the same renin- angiotensin-AT1 receptor pathway. Although for many years it was argued 'the more blockade, the better', recent trials (ONTARGET, ALTITUDE) have shown that this is not the case. In fact, at perhaps slightly more benefit, there are also more side effects (hypotension, hyperkalemia, renal dysfunction). Clearly therefore, we have reached the maximum benefit that can be obtained from blocking this pathway, and we need new pathways to interfere with. Indeed, in the last few years multiple new RAS pathways have emerged that are worth exploring: the (pro) renin receptor, the AT2 receptor (which appears to be stimulated by an angiotensin II metabolite, angiotensin-(2-8)) and the ACE2-angiotensin-(1-7)-Mas receptor pathway. In addition, angiotensin II stimulates the synthesis and release of aldosterone (hence the system is also called the renin-angiotensin- aldosterone system, RAAS). Aldosterone receptor antagonists are now important tools in resistant hypertension, whereas simultaneously new aldosterone receptors emerge (e.g., GPR30), and aldosterone synthase inhibitors are being tested as potential treatment modalities. The first AT2 receptor (ant) agonists are currently being evaluated clinically, and this is also tre for various drugs interfering with the ACE2- angiotensin-(1-7)-Mas receptor pathway (e.g., in acute respiratory stress syndrome). Clearly, at present, the RA(A)S field is rapidly moving ''beyond'' angiotensin II, the classical end-product of this system, and many new drugs start to emerge, also including drugs that acts on one specific signaling pathway of angiotensin II (''biased AT1 receptor agonists''). The Angiotensin GRC is the only meeting where these topics come together in one meeting. It is THE discussion place for the latest discoveries in the RAS, involving basic scientists and clinicians, and combined with a GRS Seminar also attracts a lot of young investigators from academia and industry. Allowing their interaction will help to move the field forward, thus making multiple new drugs available to patients ASAP.

描述（由申请人提供）：肾素 - 血管紧张素系统（RAS）在几乎每种心血管疾病中都起着至关重要的作用，目前广泛使用阻止该系统的药物。可以区分三类（肾素抑制剂，ACE抑制剂和血管紧张素II型1型（AT1）受体拮抗剂），本质上所有这些都阻止了相同的肾上腺素 - 血管紧张素-AT1受体途径。尽管多年来一直认为“越来越多的封锁”，最近的审判（安大略省，海拔）表明并非如此。实际上，也许有些好处，还有更多的副作用（低血压，高钾血症，肾功能障碍）。因此，显然，我们已经达到了通过阻止这一途径获得的最大收益，我们需要新的途径来干扰。确实，在过去的几年中，出现了值得探索的多种新的RAS途径：（Pro）肾素受体，AT2受体（似乎是由血管紧张素II代谢物，血管紧张素 - （2-8））和ACE2-血管紧张素（1-7） - Mas受体途径刺激的。此外，血管紧张素II刺激醛固酮的合成和释放（因此，该系统也称为肾素 - 血管紧张素 - 醛固酮系统RAAS）。醛固酮受体拮抗剂现在是耐药性高血压的重要工具，而同时出现了新的醛固酮受体（例如GPR30），并且正在将醛固酮合酶抑制剂作为潜在的治疗方式测试。目前正在临床评估第一个AT2受体（ANT）激动剂，这也是干扰ACE2-血管紧张素 - （1-7） - Mas受体途径的各种药物的TRE（例如，在急性呼吸胁迫综合征中）。显然，目前，RA（a）s领域正在迅速移动“超越”血管紧张素II，该系统的经典终产物，许多新药开始出现，还包括作用于血管紧张素II的一种特定信号通路的药物（''''''''''''''''''''''''''''''AT1受体受体激动剂''）。血管紧张素GRC是唯一一次在一次会议中汇聚在一起的会议。这是RAS中最新发现的讨论场所，涉及基础科学家和临床医生，并与GRS研讨会相结合，还吸引了许多来自学术界和工业的年轻调查员。允许他们的相互作用将有助于向前推动该领域的前进，从而使患者尽快可以使用多种新药。